ASLAN Pharmaceuticals Ltd ADR Logo
US04522R2004
ASLN

ASLAN Pharmaceuticals Ltd ADR

Forecast

Buy
  4
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, ASLAN Pharmaceuticals Ltd ADR had revenue of €10.86M and net profit of -€40M

(EUR) 2023
YoY
Revenue 10.86M -
Gross profit 10.54M 3,507.96%
Net profit -40M 16.49%
EBITDA -35.64M 19.12%

Fundamentals

Metric Value
Market capitalization
€708.23M
Number of shares
1.3B
52-week high/low
€15.53 - €0.43
Dividends No
Beta
1.40
P/E ratio
-0.06
PEG ratio
0.00
P/B ratio
-0.19
P/S ratio
64.76

Company profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Name
ASLAN Pharmaceuticals Ltd ADR
CEO
Carl Alan Jason Morton Firth EMBA,
Headquarters Singapore,
Singapore
Website
Industry
Chemicals
IPO
05/04/2018
Employees 35

Ticker symbols

Exchange Symbol
NASDAQ
ASLN
🍪

Parqet  uses cookies. Learn more